Search Results - Lode J. Swinnen

Refine Results
  1. 1
    Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease

    Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease by Qian Tao, Lode J. Swinnen, Jie Yang, Gopesh Srivastava, Keith D. Robertson, Richard F. Ambinder

    Published 1999
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1

    Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation1 by Wida S. Cherikh, H. Myron Kauffman, Maureen McBride, Jude Maghirang, Lode J. Swinnen, Douglas W. Hanto

    Published 2003
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma

    Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma by Matthias Holdhoff, Maciej M. Mrugała, Christian Grommes, Thomas Kaley, Lode J. Swinnen, Carlos A. Perez-Heydrich, Lakshmi Nayak

    Published 2020
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)

    Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperati... by Kristen N. Ganjoo, Fangxin Hong, Sandra J. Horning, Randy D. Gascoyne, Yasodha Natkunam, Lode J. Swinnen, Thomas M. Habermann, Brad S. Kahl, Ranjana H. Advani

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

    Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study by Sandra J. Horning, Malik E. Juweid, Heiko Schöder, Gregory A. Wiseman, Alex McMillan, Lode J. Swinnen, Ranjana H. Advani, Randy D. Gascoyne, Andrew Quon

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)

    Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404) by Lode J. Swinnen, Hailun Li, Andrew Quon, Randy D. Gascoyne, Fangxin Hong, Erik A. Ranheim, Thomas M. Habermann, Brad S. Kahl, Sandra J. Horning, Ranjana H. Advani

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage

    Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage by Genevieve M. Crane, Helen Powell, Rumen Kostadinov, Patrick Tim Rocafort, Dena E. Rifkin, Peter C. Burger, Richard F. Ambinder, Lode J. Swinnen, Michael J. Borowitz, Amy S. Duffield

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

    Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder by Lode J. Swinnen, Michael LeBlanc, Thomas M. Grogan, Leo I. Gordon, Patrick J. Stiff, Alan M. Miller, Yvette L. Kasamon, Thomas P. Miller, Richard I. Fisher

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients

    Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant Recipients by Lode J. Swinnen, Maria Rosa Costanzo‐Nordin, Susan G. Fisher, E. Jeanne O'Sullivan, Maryl R. Johnson, Alain Heroux, George J. Dizikes, R Pifarré, Richard I. Fisher

    Published 1990
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS

    EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS by Carlos V. Payá, John J. Fung, Michael A. Nalesnik, Elliott Kieff, Michael Green, Gregory Gores, Thomas M. Habermann, Russell H. Wiesner, Lode J. Swinnen, E. Steve Woodle, Jonathan S. Bromberg

    Published 1999
    Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide

    Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide by Laura Schoch, Kenneth R. Cooke, Nina D. Wagner‐Johnston, Ivana Gojo, Lode J. Swinnen, Philip Imus, Ephraim J. Fuchs, Mark J. Levis, Richard F. Ambinder, Richard J. Jones, Douglas E. Gladstone

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning

    Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning by Yvette L. Kasamon, Richard L. Wahl, Harvey A. Ziessman, Amanda L. Blackford, Steven N. Goodman, Caroline A. Fidyk, Kathryn Rogers, Javier Bolaños‐Meade, Michael J. Borowitz, Richard F. Ambinder, Richard J. Jones, Lode J. Swinnen

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma

    Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma by Yvette L. Kasamon, Heather A. Jacene, Christopher D. Gocke, Lode J. Swinnen, Douglas E. Gladstone, Brandy Perkins, Brian K. Link, Leslie Popplewell, Thomas M. Habermann, Joseph M. Herman, William Matsui, Richard J. Jones, Richard F. Ambinder

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma

    Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma by Jennifer A. Kanakry, Yvette L. Kasamon, Christopher D. Gocke, Hua-Ling Tsai, Janice Davis‐Sproul, Nilanjan Ghosh, Heather J. Symons, Javier Bolaños‐Meade, Douglas E. Gladstone, Lode J. Swinnen, Leo Luznik, Ephraim J. Fuchs, Richard J. Jones, Richard F. Ambinder

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

    Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402 by Brad S. Kahl, Fangxin Hong, Michael E. Williams, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss, Thomas M. Habermann, Lode J. Swinnen, Stephen J. Schuster, Christopher G. Peterson, Mark D. Sborov, Sabrina Martín, Matthias Weiss, W. Christopher Ehmann, Sandra J. Horning

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402

    Rituximab extended schedule or retreatment trial for low tumour burden non‐follicular indolent B‐cell non‐Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402 by Michael E. Williams, Fangxin Hong, Randy D. Gascoyne, Lynne I. Wagner, John C. Krauss, Thomas M. Habermann, Lode J. Swinnen, Stephen J. Schuster, Christopher G. Peterson, Mark D. Sborov, Sabrina Martín, Matthias Weiss, W. Christopher Ehmann, Sandra J. Horning, Brad S. Kahl

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide

    Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide by Yvette L. Kasamon, Richard F. Ambinder, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Javier Bolaños‐Meade, Mark J. Levis, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, William Matsui, Ivan Borrello, Robert A. Brodsky, Richard J. Jones, Leo Luznik

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

    Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101 by Tracy T. Batchelor, Sharmila Giri, Amy S. Ruppert, Susan M. Geyer, Scott E. Smith, Nimish Mohile, Lode J. Swinnen, Jonathan W. Friedberg, Brad S. Kahl, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Nina D. Wagner‐Johnston, Lakshmi Nayak, John P. Leonard, James L. Rubenstein

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation

    Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation by Yvette L. Kasamon, Ephraim J. Fuchs, Marianna Zahurak, Gary L. Rosner, Heather J. Symons, Douglas E. Gladstone, Carol Ann Huff, Lode J. Swinnen, Robert A. Brodsky, William Matsui, Ivan Borrello, Satish Shanbhag, Kenneth R. Cooke, Richard F. Ambinder, Leo Luznik, Javier Bolaños‐Meade, Richard J. Jones

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation

    Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation by Philip Imus, Amanda L. Blackford, Maria Bettinotti, Brian Iglehart, August Dietrich, Noah Tucker, Heather J. Symons, Kenneth R. Cooke, Leo Luznik, Ephraim J. Fuchs, Robert A. Brodsky, William Matsui, Carol Ann Huff, Douglas E. Gladstone, Richard F. Ambinder, Ivan Borrello, Lode J. Swinnen, Richard J. Jones, Javier Bolaños‐Meade

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: